| Heading: |
Dementia: Clinical Trials |
| Question ID: |
1805090 |
| UIN: |
54158 |
| House: |
Commons |
| Date tabled: |
2025-05-21 |
| Asking Member ID: |
5238 |
| Asking Member display name: |
Alex Ballinger
|
| Asking Member handle: |
AlexBallingerMP
|
| Asking Member Twitter reference: |
@AlexBallingerMP
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the UK’s capacity to attract investment in dementia clinical trials, in the context of the availability of disease-modifying treatments in other countries |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-05 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4981 |
| Answering Member display name: |
Ashley Dalton
|
| Answering Member handle: |
AshleyDalton_MP
|
| Answering Member Twitter reference: |
@AshleyDalton_MP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
No particular assessment has been made.The Department is committed to turbocharging medical research and delivering better patient care, to make the United Kingdom a world-leading destination for clinical research. We are working to fast-track clinical tr... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |